Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
GBT's Cash-to-Debt is ranked higher than
65% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. GBT: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
GBT' s Cash-to-Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Interest Coverage No Debt
GBT's Interest Coverage is ranked higher than
53% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GBT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
GBT' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 46.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE % -42.58
GBT's ROE % is ranked lower than
57% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. GBT: -42.58 )
Ranked among companies with meaningful ROE % only.
GBT' s ROE % Range Over the Past 10 Years
Min: -110.51  Med: -80.47 Max: -42.58
Current: -42.58
-110.51
-42.58
ROA % -39.83
GBT's ROA % is ranked lower than
61% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. GBT: -39.83 )
Ranked among companies with meaningful ROA % only.
GBT' s ROA % Range Over the Past 10 Years
Min: -293.52  Med: -56.87 Max: -39.83
Current: -39.83
-293.52
-39.83
ROC (Joel Greenblatt) % -3671.58
GBT's ROC (Joel Greenblatt) % is ranked lower than
77% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. GBT: -3671.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GBT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3671.58  Med: -1588.74 Max: -662
Current: -3671.58
-3671.58
-662
GuruFocus has detected 1 Warning Sign with Global Blood Therapeutics Inc $GBT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GBT's 30-Y Financials

Financials (Next Earnings Date: 2017-08-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

GBT Guru Trades in Q2 2016

Paul Tudor Jones 26,243 sh (New)
Steven Cohen Sold Out
» More
Q3 2016

GBT Guru Trades in Q3 2016

Jim Simons 101,200 sh (New)
Paul Tudor Jones Sold Out
» More
Q4 2016

GBT Guru Trades in Q4 2016

Jim Simons Sold Out
» More
Q1 2017

GBT Guru Trades in Q1 2017

Steven Cohen 411,100 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with GBT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325411    SIC: 2834
Compare:NAS:LOXO, NAS:DERM, NAS:FOLD, NYSE:EBS, NAS:INVA, NAS:RGEN, OTCPK:GNFTF, NAS:CHRS, OTCPK:PHMMF, NAS:CORT, NAS:ARRY, NAS:INSY, OTCPK:PFSCF, NAS:BPMC, NAS:INSM, NAS:XNCR, NAS:XLRN, NAS:BGNE, NAS:FWP, NAS:EPZM » details
Traded in other countries:G5B.Germany,
Headquarter Location:USA
Global Blood Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with unmet need.

Global Blood Therapeutics Inc was incorporated under the laws of the State of Delaware in February 2011. It is a biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It is developing its initial product candidate, GBT440, as a once-daily, oral prophylactic therapy for sickle cell disease, or SCD, and are currently evaluating GBT440 in both healthy subjects and SCD patients in a randomized, placebo-controlled, double-blind Phase 1/2 clinical trial. SCD is a disease marked by severe pain "crises," recurrent hospitalizations, multi-organ damage, and early mortality. GBT440 is a novel hemoglobin modifier that binds to hemoglobin molecules. Oxyhemoglobin, or hemoglobin in the oxygenated state, is a potent inhibitor of HbS polymerization. Its patent portfolio includes three issued U.S. patents, two allowed U.S. patent applications, and several U.S. and foreign patent applications in the early stages of prosecution.

Top Ranked Articles about Global Blood Therapeutics Inc

Global Blood Therapeutics Reports Recent Business Progress and Provides First Quarter 2017 Financial Results
Global Blood Therapeutics to Present at the 16th Annual Needham Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (NASDAQ:GBT) (NASDAQ:GBT), today announced that it will present at the 16th Annual Needham Healthcare Conference in New York, NY on Wednesday, April 5 at 12:10 p.m. Eastern Time.
The presentation will be webcast live and available for replay from GBT’s website at www.globalbloodtx.com in the Investors section. About Global Blood Therapeutics
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease. GBT is also investigating GBT440 for the treatment of hypoxemic pulmonary disorders in two ongoing Phase 2a studies in patients with idiopathic pulmonary fibrosis. To learn more, please visit: www.globalbloodtx.com and follow the company on Twitter: @GBT_News. Forward-Looking Statements
Statements we make in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. We intend these forward-looking statements, including statements regarding the therapeutic potential and safety profile of GBT440, and our ability to implement our clinical development plans for GBT440, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved, and furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, the risks that our clinical and preclinical development activities may be delayed or terminated for a variety of reasons, that regulatory authorities may disagree with our clinical development plans or require additional studies or data to support further clinical investigation of our product candidates, and that drug-related adverse events may be observed in later stages of clinical development, along with those risks set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, and in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2016, June 30, 2016 and September 30, 2016, as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Information:
Myesha Lacy (investors)
GBT
650-351-4730
[email protected]

Julie Normart (media)
Pure Communications
415-946-1087
[email protected]

Read more...
Global Blood Therapeutics Reports Recent Business Progress and Fourth Quarter and Year-End 2016 Financial Results

SOUTH SAN FRANCISCO, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (NASDAQ:GBT) (NASDAQ:GBT) today reported business progress and financial results for the fourth quarter and year ended December 31, 2016.
"2016 was a year of consistent execution and rapid advancement across both of our GBT440 clinical programs designed to treat diseases where the patient communities are greatly underserved. This was highlighted by coming to agreement with the FDA on the design of our pivotal HOPE Study in patients with sickle cell disease (SCD). The HOPE Study is a uniquely designed trial that has a strong grounding in GBT440’s mechanism of action, including its potential to fundamentally modify the course of the disease by inhibiting sickle hemoglobin polymerization,” said Ted W. Love, M.D., president and chief executive officer of GBT. “In 2017, we will remain focused on advancing both our SCD and idiopathic pulmonary fibrosis (IPF) programs. We will continue to enroll patients in our pivotal HOPE Study, as well as reporting data from our three ongoing studies that support our IPF program -- two Phase 2a trials in IPF patients and a Phase 1 study evaluating the effect of GBT440 on oxygen saturation in healthy volunteers. Given our recent financing we expect our cash and investments as well as proceeds from the financing will allow us to fund all currently planned activities through the announcement of topline data from our SCD pivotal study.” Recent Business Progress Sickle Cell Disease (SCD) Announced enrollment of the first patient in the HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study, a pivotal Phase 3 clinical trial of GBT440 in people with SCD. The HOPE Study will be conducted at leading SCD sites globally and is expected to enroll up to 400 adults and adolescents with SCD who have had at least one episode of vaso-occlusive crisis (VOC) in the previous year.Presented new details on the novel patient reported outcome (PRO) tool to be used as a secondary clinical endpoint in the HOPE Study at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition. The nine-item Sickle Cell Disease Severity Measure (SCDSM) has been designed by GBT to assess the entire range of SCD symptoms, to distinguish between good days and bad days based on symptoms and to measure all crisis events regardless of health care utilization.Presented at ASH new long-term clinical data from the ongoing Phase 1/2 trial of GBT440 in SCD that further support the safety and efficacy profile of GBT440 as a potentially disease-modifying therapy. Results showing how GBT440 is metabolized in healthy subjects were also presented.The European Commission (EC), acting on a positive recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), designated GBT440 as an orphan medicinal product for the treatment of SCD.A paper describing the discovery of GBT440 and its ability to bind to hemoglobin and prevent red blood cells from sickling was published online in ACS Medicinal Chemistry Letters, a peer-reviewed publication of the American Chemical Society. Hypoxemic Pulmonary Disorders Enrolled the first patient in the Phase 1 Basecamp clinical trial evaluating the effect of GBT440 on oxygen saturation (the level of oxygen in the blood) in healthy volunteers at rest and following maximal exercise under hypoxic conditions.Enrolled the first patient in ZEPHYR, a Phase 2a clinical trial evaluating the safety and efficacy of GBT440 for the treatment of hypoxemia in patients with idiopathic pulmonary fibrosis (IPF) who are on supplemental oxygen at rest. Corporate Selected for addition to the NASDAQ Biotechnology Index® (NBI).Raised approximately $135.6 million in net proceeds, after deducting underwriting discounts and commissions and estimated offering expenses, from an underwritten public offering of 5,867,347 shares of common stock in February 2017.  Summary Financial Results for the Fourth Quarter and Year-End 2016 Cash, cash equivalents, and marketable securities totaled $197.3 million at December 31, 2016 compared with $148.5 million at December 31, 2015. Net loss for the three months ended December 31, 2016 was $27.2 million compared with $15.6 million for the same period in 2015. Basic and diluted net loss per share attributable to common stockholders for the three months ended December 31, 2016 was $0.74 compared with $0.53 for the same period in 2015. Net loss for the year ended December 31, 2016 was $82.5 million compared with $46.4 million for the same period in 2015. Basic and diluted net loss per share attributable to common stockholders for the year ended December 31, 2016 was $2.48 compared with $3.95 for the same period in 2015. Research and development (R&D) expenses for the three months ended December 31, 2016 were $20.4 million compared with $11.4 million for the same period in 2015. R&D expenses for the year ended December 31, 2016 were $61.2 million compared with $36.7 million for the same period in 2015. The increase in R&D expenses for both comparative periods is primarily attributable to increased expenses related to the Company's development of GBT440 for the treatment of SCD and for the treatment of IPF, including the ongoing Phase 1/2 clinical trial in SCD, initiation of our Phase 2a clinical trial in adolescent patients with SCD, start-up costs related to the pivotal HOPE Study, initiation of two Phase 2a clinical trials of GBT440 in IPF, and preclinical pipeline programs. Total R&D stock compensation expense incurred for the three months ended December 31, 2016 was $1.6 million, compared with $0.8 million for the same period in 2015. Total R&D stock compensation expense incurred for the year ended December 31, 2016 was $3.7 million, compared with $2.0 million for the same period in 2015. General and administrative (G&A) expenses for the three months ended December 31, 2016 were $7.1 million compared with $4.2 million for the same period in 2015. G&A expenses for the year ended December 31, 2016 were $21.9 million compared with $9.7 million for the same period in 2015. The increase in G&A expenses for both comparative periods is primarily attributable to increased employee-related costs associated with the growth of the Company's operations. Total G&A stock compensation expense incurred in the three months ended December 31, 2016 was $1.7 million, compared with $0.7 million for the same period in 2015. Total G&A stock compensation expense incurred in the year ended December 31, 2016 was $5.5 million, compared with $1.2 million for the same period in 2015. About Global Blood Therapeutics
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease. GBT is also investigating GBT440 for the treatment of hypoxemic pulmonary disorders in two ongoing Phase 2a studies in patients with idiopathic pulmonary fibrosis. To learn more, please visit: www.globalbloodtx.com and follow the company on Twitter: @GBT_News. Forward-Looking Statements
Statements we make in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. We intend these forward-looking statements, including statements regarding the therapeutic potential and safety profile of our lead product candidate GBT440 and any of our other product candidates, our ability to implement our clinical and other development plans for our product candidates, the timing of our clinical studies of our product candidates, our ability to generate any data or positive data from our studies of our product candidates, our ability to enroll patients in our clinical studies including our Phase 3 HOPE Study of GBT440 and our anticipated cash runway, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved, and furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, the risks that achievement of our business goals will require substantial additional funding that may not be available, the risks that our clinical and other development activities may be delayed or terminated for a variety of reasons, the risks that regulatory authorities may disagree with our development plans or interpretation of data or may require additional studies or data to support any approval of our product candidates, and the risks that our product candidates may not demonstrate therapeutic potential or may result in drug-related adverse events along with those risks set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, and in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2016, June 30, 2016 and September 30, 2016, as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.   GLOBAL BLOOD THERAPEUTICS, INC.Condensed Consolidated Statements of Operations(In thousands, except share and per share amounts)  Three Months Ended
December 31, Years Ended
December 31, 2016 2015 2016 2015             (Unaudited)    Operating expenses:       Research and development$20,365  $11,400  $61,212  $36,657 General and administrative7,095  4,198  21,915  9,736 Total operating expenses27,460  15,598  83,127  46,393 Loss from operations(27,460) (15,598) (83,127) (46,393)Interest and other income, net252  13  659  33 Net loss$(27,208) $(15,585) $(82,468) $(46,360)Net loss attributable to common stockholders$(27,208) $(15,585) $(82,468) $(50,540)Net loss per share attributable to common stockholders, basic and diluted$(0.74) $(0.53) $(2.48) $(3.95)Weighted-average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted36,580,582  29,317,707  33,207,382  12,806,697             
GLOBAL BLOOD THERAPEUTICS, INC.
 Condensed Consolidated Balance Sheets
 (In thousands, except share and per share amounts)
               December 31,
2016
  December 31,
2015
        (1)
 Assets          Current assets:          Cash and cash equivalents $ 92,072  $ 148,502 Short-term marketable securities  55,202   â€” Prepaid expenses and other current assets  2,495   1,222 Total current assets  149,769   149,724 Long-term marketable securities  50,058   â€” Other assets  2,560   2,254 Total assets $ 202,387
  $ 151,978 Liabilities and Stockholders’ Equity          Current liabilities $15,515  $9,627 Other liabilities, noncurrent  563   1,556 Total liabilities  16,078   11,183 Total Stockholders’ equity  186,309   140,795 Total liabilities and stockholders’ equity $ 202,387  $ 151,978                     (1) Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year’s presentation.  

Contact Information:
Myesha Lacy (investors)
GBT
650-351-4730
[email protected]

Julie Normart (media)
Pure Communications
415-946-1087
[email protected]

Read more...
Global Blood Therapeutics Announces Participation at Two Upcoming Investor Conferences in March

SOUTH SAN FRANCISCO, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (NASDAQ:GBT) (NASDAQ:GBT), today announced that it will present at the following investor conferences in March:
Cowen and Company 37th Annual Health Care Conference in Boston, MA on Tuesday, March 7, 2017 at 8:40 a.m. Eastern Time (ET); andThe 29th Annual ROTH Conference in Dana Point, CA on Tuesday, March 14, 2017 at 4:30 p.m. Pacific Time (PT). The presentations will be webcast live and available for replay from GBT’s website at www.globalbloodtx.com in the Investors & Media section. About Global Blood Therapeutics
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease. GBT is also investigating GBT440 for the treatment of hypoxemic pulmonary disorders including idiopathic pulmonary fibrosis. To learn more, please visit: www.globalbloodtx.com and follow the company on Twitter: @GBT_News. Forward-Looking Statements
Statements we make in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. We intend these forward-looking statements, including statements regarding the therapeutic potential and safety profile of GBT440, and our ability to implement our clinical development plans for GBT440, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved, and furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, the risks that our clinical and preclinical development activities may be delayed or terminated for a variety of reasons, that regulatory authorities may disagree with our clinical development plans or require additional studies or data to support further clinical investigation of our product candidates, and that drug-related adverse events may be observed in later stages of clinical development, along with those risks set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, and in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2016, June 30, 2016 and September 30, 2016, as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Information:
Myesha Lacy (investors)
GBT
650-351-4730
[email protected]

Julie Normart (media)
Pure Communications
415-946-1087
[email protected]



Read more...

Ratios

vs
industry
vs
history
PB Ratio 3.99
GBT's PB Ratio is ranked lower than
76% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. GBT: 3.99 )
Ranked among companies with meaningful PB Ratio only.
GBT' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 7.36
Current: 3.99
0
7.36
EV-to-EBIT -10.72
GBT's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. GBT: -10.72 )
Ranked among companies with meaningful EV-to-EBIT only.
GBT' s EV-to-EBIT Range Over the Past 10 Years
Min: -19.24  Med: 0 Max: 0
Current: -10.72
-19.24
0
EV-to-EBITDA -10.90
GBT's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. GBT: -10.90 )
Ranked among companies with meaningful EV-to-EBITDA only.
GBT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.55  Med: 0 Max: 0
Current: -10.9
-19.55
0
Current Ratio 16.84
GBT's Current Ratio is ranked higher than
77% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. GBT: 16.84 )
Ranked among companies with meaningful Current Ratio only.
GBT' s Current Ratio Range Over the Past 10 Years
Min: 8.1  Med: 16.19 Max: 24.45
Current: 16.84
8.1
24.45
Quick Ratio 16.84
GBT's Quick Ratio is ranked higher than
78% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. GBT: 16.84 )
Ranked among companies with meaningful Quick Ratio only.
GBT' s Quick Ratio Range Over the Past 10 Years
Min: 8.1  Med: 16.19 Max: 24.45
Current: 16.84
8.1
24.45

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 5.28
GBT's Price-to-Net-Cash is ranked lower than
68% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. GBT: 5.28 )
Ranked among companies with meaningful Price-to-Net-Cash only.
GBT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.75  Med: 4.13 Max: 8.53
Current: 5.28
2.75
8.53
Price-to-Net-Current-Asset-Value 5.18
GBT's Price-to-Net-Current-Asset-Value is ranked lower than
69% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. GBT: 5.18 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GBT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.72  Med: 4.06 Max: 8.42
Current: 5.18
2.72
8.42
Price-to-Tangible-Book 3.99
GBT's Price-to-Tangible-Book is ranked lower than
68% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. GBT: 3.99 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GBT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.69  Med: 4.01 Max: 8.29
Current: 3.99
2.69
8.29
Earnings Yield (Greenblatt) % -9.33
GBT's Earnings Yield (Greenblatt) % is ranked higher than
52% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. GBT: -9.33 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GBT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -266.48  Med: 0 Max: 0
Current: -9.33
-266.48
0

More Statistics

EPS (TTM) $ -2.52
Short Percentage of Float11.44%
52-Week Range $13.35 - 41.15
Shares Outstanding (Mil)43.61

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -2.76 -3.01 -3.51
EPS without NRI ($) -2.76 -3.01 -3.51
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for GBT

Headlines

Articles On GuruFocus.com

More From Other Websites
Global Blood Therapeutics Announces Upcoming Presentation of GBT440 Data in Adolescents with Sickle... May 18 2017
Global Blood reports 1Q loss May 01 2017
Global Blood Therapeutics Reports Recent Business Progress and Provides First Quarter 2017 Financial... May 01 2017
5 Top Performing Stocks of the Best ETF of Q1 Mar 30 2017
Global Blood Therapeutics to Present at the 16th Annual Needham Healthcare Conference Mar 29 2017
Market Is Home on the Range Again Mar 22 2017
Global Blood Therapeutics' Acquisition Value Could Be At Least $3 Billion Mar 20 2017
5 Stocks The Best Performing Hedge Funds Are Piling Into Mar 16 2017
Global Blood Therapeutics Demonstrates 'Compelling Potential' In Sickle Cell Treatment Mar 16 2017
Market Takes 'National Napping Day' Seriously Mar 13 2017
Global Blood Therapeutics Reports Recent Business Progress and Fourth Quarter and Year-End 2016... Mar 13 2017
Biotech Leads the Way Again Today Mar 13 2017
These 3 Stocks Have Doubled Investors' Money Mar 13 2017
Late Market Rally but No Bounce for Bulls Mar 10 2017
Adam Feuerstein Weighs In On Novo-GBT Rumors, Undue Sarepta Volatility, Unprofitable Business Of... Mar 10 2017
Here’s Our Take On The Global Blood Therapeutics Inc (GBT) Rumors Mar 10 2017
Biotech Reporter Adam Feuerstein Will Be On Benzinga's PreMarket Prep Friday Morning Mar 09 2017
Novo Nordisk in Talks to Buy Global Blood Therapeutics (NVO,GBT) Mar 09 2017
Market Set Up for Oversold Bounce Mar 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)